Omeprazol Azevedos (Omeprazole)

Omeprazol Azevedos is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related gastrointestinal conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine disorder.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.
• NSA‑related ulcer prophylaxis: lowers ulcer risk in patients requiring long‑term non‑steroidal anti‑inflammatory drug therapy.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this final step of acid secretion, it markedly reduces both basal and stimulated gastric acidity, allowing the mucosal lining to heal and decreasing reflux of acid into the oesophagus.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhoea: loose stools, usually self‑limiting.
• Abdominal pain: mild discomfort or cramping.
• Nausea: occasional feeling of queasiness.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis linked to altered gut flora.
• Acute interstitial nephritis: sudden kidney inflammation.
• Hypomagnesemia: low serum magnesium with prolonged use.
• Stevens‑Johnson syndrome: rare severe skin reaction.
• Fracture risk: possible reduction in bone mineral density with long‑term therapy.
• Liver enzyme elevation: increased ALT/AST levels in rare cases.

When prescribing Omeprazol Azevedos, clinicians should consider several safety aspects:

• Assess renal function: adjust use in patients with severe renal impairment.
• Review concomitant medications: monitor for reduced efficacy of drugs requiring acidic pH for absorption.
• Evaluate bone health: long‑term therapy may affect calcium absorption and bone density.
• Monitor magnesium levels: prolonged use can lead to hypomagnesemia.
• Pregnancy and lactation: use only if clearly needed; weigh potential benefits against risks.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole may interact with several medicines, requiring clinical awareness:

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk.
• Atazanavir: decreased absorption, compromising antiviral efficacy.
• Dasatinib: lowered plasma concentrations, reducing therapeutic effect.

Moderate Interactions (Monitor Closely):

• Warfarin: potential increase in INR values.
• Phenytoin: possible reduction in phenytoin levels.
• Digoxin: altered serum concentrations.
• Ketoconazole: decreased absorption due to higher gastric pH.